Sanofi (SNY): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Sanofi, located in Paris, France, develops and manufactures pharmaceutical products, primarily for sale in the prescription drug market. The company, which has global operations, focuses on major therapeutic areas such as cardiovascular, central nervous system, oncology and internal medicine formulations. Sanofi manufactures and markets prescription drugs in Europe, the U.S. and other countries. Lantus is the lead product in the company's diabetes franchise. In Apr 2011, Genzyme Corporation became a subsidiary of Sanofi. With this deal, Sanofi has expanded its presence in biotech and now has products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio.

Sanofi's pipeline includes several late-stage candidates including Cerdelga (for Gaucher disease, under review in EU and U.S.), alirocumab (hypercholesterolemia, phase III) and sarilumab (rheumatoid arthritis, phase III). Lyxumia, approved in the EU, is currently in phase III trial in the U.S.

Sanofi has a strong presence throughout Europe and has been growing its operations in the U.S. Sanofi also has a growing generic drugs business the company acquired Zentiva, a large generics company with a major presence in the Czech Republic, Turkey, Romania and Slovakia.

Sanofi has collaboration agreements with pharmaceutical companies like Bristol-Myers Squibb, Teva and Merck among others.

In 2013, total sales decreased 0.5% (CER) to 33.0 billion. Generic competition hampered revenues by 1.3 billion.

Geographical Break-Up of 2013 Revenues

Segmental Break-Up of 2013 Revenues